Skip to content
Open access

Subtype-Specific Mortality and Cardiovascular Burden in HIV Patients with Steatotic Liver Disease: A Korean National Cohort Study

Aug 2026 · Gut and Liver · Vol 20, pp. 859 - 869 · 0 citations · 42 references
Medicine

TL;DR

As SLD is significantly associated with mortality in PLWH, integrated management focusing on liver health, metabolic dysfunction, and alcohol use is essential to reduce adverse outcomes.

Abstract

Background/Aims Steatotic liver disease (SLD) is an emerging comorbidity among people living with human immunodeficiency virus (PLWH), but its subtype-specific burden remains unclear. We aimed to evaluate the prevalence of SLD and its associations with mortality, cardiovascular diseases, and liver cirrhosis (LC). Methods This retrospective cohort study included 4,597 Korean PLWH using data from the National Health Insurance Service (2013–2022). SLD was defined using the fatty liver index (≥30) and categorized into metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and metabolic dysfunction-associated ALD (MetALD). Outcomes were all-cause mortality, cardiovascular diseases, and LC, analyzed using multivariable Cox proportional hazards and Fine–Gray competing risk models. Results The prevalence of SLD was 45.7%, predominantly MASLD (86.5%), followed by MetALD (9.7%) and ALD (3.8%). SLD prevalence in PLWH was not higher than that in matched controls. Over a median 6-year follow-up, SLD was associated with increased mortality (adjusted hazard ratio, 1.53; 95% confidence interval [CI], 1.03 to 2.29). ALD was linked to higher stroke risk (adjusted subdistribution hazard ratio [aSHR], 3.10; 95% CI, 1.04 to 9.20), and MetALD to higher LC risk (aSHR, 5.72; 95% CI, 1.48 to 22.10). Conclusions As SLD is significantly associated with mortality in PLWH, integrated management focusing on liver health, metabolic dysfunction, and alcohol use is essential to reduce adverse outcomes.

Read PDF

Similar papers

Open access Aug 2026

Unequal mortality risks in steatotic liver disease beyond liver: influence of disease subtypes and fibrosis

To examine mortality risks associated with steatotic liver disease (SLD), focusing on how disease subtypes (MASLD, MetALD, ALD), and fibrosis severity shape cause-specific mortality across a broad spectrum of diseases. We analysed 486156 UK Biobank participants. Causes of death were summarised by SLD subty...

Q. Feng, C. Izzi-Engbeaya, Mark Woodward et al. · 0 citations
Open access Sep 2026

Older people living with HIV: a population with high prevalence and severity of metabolic dysfunction-associated steatotic liver disease ‒ A cross-sectional study

MASLD was highly prevalent among older PLWH, with a substantial proportion presenting moderate-to-severe steatosis and significant fibrosis, while lipodystrophy and higher ALT levels were associated with greater steatosis severity.

R. Peixoto, A. Batista, Armando Ykaro Soares de Oliveira et al. · 0 citations
Open access Sep 2026

Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis

Background/Aims The recently proposed classification of steatotic liver disease (SLD) comprises metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Long-term cancer risk across these phenotypes remains incompletely char...

Hana Park, Ji-Young Lee, J. E. Koo et al. · 0 citations
Sep 2026

Cardiovascular-kidney-metabolic syndrome and the risk of liver-related and cardiovascular events across the steatotic liver disease spectrum.

A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.

Qiong-Yue Fan, Li-You Lian, Tian-Yi Xia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.